Inflammatory bowel disease (IBD) is an umbrella term for chronic inflammatory conditions of the digestive tract, with ulcerative colitis and Crohn's disease as the main types. It can involve recurrent active disease and remission, and severity ranges from mild illness to disabling complications.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Everest Medicines launched VELSIPITY in Mainland China after NMPA approval on February 2, 2026. The first prescription was issued at The First Affiliated Hospital of Sun Yat-sen University.
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.
A study published on February 17, 2026 validated an AI workflow that predicted colorectal cancer risk in ulcerative colitis with 99% accuracy using over 55,000 patient records. The model identified low-risk and higher-risk patients from clinical notes, colonoscopy reports, and pathology findings.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07532213 |
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab |
NOT_YET_RECRUITING | |
| NCT07475052 |
Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD |
ENROLLING_BY_INVITATION | |
| NCT07466940 |
A Clinical Study to Evaluate SM17 in Healthy Participants |
COMPLETED | PHASE1 |
| NCT07391046 |
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients |
NOT_YET_RECRUITING | |
| NCT07252427 |
Gut Microbiota in IBD With Comorbid Depressive Disorder |
RECRUITING | |
| NCT07242248 |
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK) |
RECRUITING | |
| NCT07210580 |
Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease |
RECRUITING | NA |
| NCT07207200 |
Impact of Morning Light Therapy in IBD |
RECRUITING | NA |
| NCT07167836 |
Automated Clinical Pathway for Inflammatory Bowel Disease Care |
ENROLLING_BY_INVITATION | NA |
| NCT07167745 |
Tracking the Natural Course of Silent Small Bowel Narrowing in Adults With Crohn's Disease |
COMPLETED |
